Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia
ConclusionAlthough based on a small population, this study represents an unbiased reference on the long-term management of CML in an Italian clinical setting. Our results indicate a better profile of first-line nilotinib, both in terms of persistency and tolerability. AEs remain a major concern, highlighting the importance of close monitoring.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Chronic Pain | Clinical Trials | Databases & Libraries | Dermatology | Drugs & Pharmacology | Gleevec | Italy Health | Leukemia | Nilotinib | Pain | Pain Management | Pathology | Skin | Study | Tasigna